Resonance Health Lifts FY26 Profit Guidance Amid Margin Growth.
Resonance Health Limited (ASX: RHT) has increased its FY26 underlying EBITDA outlook to around AU$2.6 million, reflecting a notable improvement of 30% compared to its earlier estimate. The upgrade is largely supported by stronger cost efficiency, better operating leverage, and a rising contribution from higher-margin services.
Although revenue expectations have been adjusted to approximately AU$16.0 million, this change is mainly due to delays in recognising income from a significant clinical trial, with earnings expected to shift into the following year. Despite this, profitability is anticipated to improve meaningfully.
Growth has been driven by the company’s Software-as-Medical Devices segment, clinical trial services, and expanded operational capacity. Continued investment in automation and process optimisation has further strengthened performance. Looking ahead, the company is supported by a solid contract pipeline, global expansion potential, and increasing demand for advanced medical imaging solutions, positioning it well for sustained long-term growth and improved margins.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Resonance Health Lifts FY26 Profit Guidance Amid Margin Growth.
Resonance Health Limited (ASX: RHT) has increased its FY26 underlying EBITDA outlook to around AU$2.6 million, reflecting a notable improvement of 30% compared to its earlier estimate. The upgrade is largely supported by stronger cost efficiency, better operating leverage, and a rising contribution from higher-margin services.
Although revenue expectations have been adjusted to approximately AU$16.0 million, this change is mainly due to delays in recognising income from a significant clinical trial, with earnings expected to shift into the following year. Despite this, profitability is anticipated to improve meaningfully.
Growth has been driven by the company’s Software-as-Medical Devices segment, clinical trial services, and expanded operational capacity. Continued investment in automation and process optimisation has further strengthened performance. Looking ahead, the company is supported by a solid contract pipeline, global expansion potential, and increasing demand for advanced medical imaging solutions, positioning it well for sustained long-term growth and improved margins.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au